Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder

This was a prospective, multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled clinical trial. Qualified subjects, according to the ratio of 1:1:1, were randomized into Crisugabalin group, Venlafaxine-control group and placebo-control group, and received a double-blind treatment course of 8 weeks. After completing the 8-week double-blind treatment period, subjects will officially conclude the study or voluntarily enter a 4-week open-label extension treatment phase. During the open-label extension phase, all subjects will receive Crisugabalin 80 mg/day (40 mg bid). Participants were followed from baseline outpatient visit until end of the follow-up period (14 weeks and 9 visits in total).